Literature DB >> 16384848

Molecular pathology of Muller's muscle in Graves' ophthalmopathy.

Mei-Ju Shih1, Shu-Lang Liao, Kuan-Ting Kuo, Terry J Smith, Lee-Ming Chuang.   

Abstract

CONTEXT: Upper lid retraction is a common sign in Graves' ophthalmopathy (GO). Whether Müller's muscle is involved in upper lid retraction has not been fully elucidated.
OBJECTIVE: The objective of the study was to understand the molecular pathology of Müller's muscle in GO. DESIGN/SETTING/PARTICIPANTS: A method for measurement of histological changes was developed and used to correlate severity and expression of cell-specific genes in GO. MAIN OUTCOME MEASURES: Histological changes, clinical severity of upper lid retraction, and mRNA expression in Müller's muscle in GO were measured.
RESULTS: The degree of fibrosis correlates with severity of upper lid retraction. Macrophage infiltration was increased in fibrotic areas, consistent with higher levels of macrophage-colony stimulating factor mRNA. Levels of peroxisome proliferator-activated receptor-gamma mRNA were up-regulated and correlated with fat infiltration. Decreased muscle mass correlated with lower myocardin mRNA expression. The expression of c-kit levels was decreased in diseased muscles, consistent with diminished mast cell numbers.
CONCLUSION: The pathological changes of Müller's muscle correlate with clinical severity of upper lid retraction in GO. Patterns of gene expression appear to correlate with the histopathological changes in this disease process.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16384848     DOI: 10.1210/jc.2005-1877

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

1.  Statin reduces orbitopathy risk in patients with Graves' disease by modulating apoptosis and autophagy activities.

Authors:  Maurizio Bifulco; Elena Ciaglia
Journal:  Endocrine       Date:  2015-10-05       Impact factor: 3.633

2.  Relationships between eyelid position and levator-superior rectus complex and inferior rectus muscle in patients with Graves' orbitopathy with unilateral upper eyelid retraction.

Authors:  Jun Soo Byun; Jeong Kyu Lee
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-06-29       Impact factor: 3.117

Review 3.  Cholesterol Serum Levels and Use of Statins in Graves' Orbitopathy: A New Starting Point for the Therapy.

Authors:  Giulia Lanzolla; Guia Vannucchi; Ilaria Ionni; Irene Campi; Federica Sileo; Elisa Lazzaroni; Michele Marinò
Journal:  Front Endocrinol (Lausanne)       Date:  2020-01-22       Impact factor: 5.555

Review 4.  Management of eyelid retraction related to thyroid eye disease.

Authors:  Tammy H Osaki; Lucas G Monteiro; Midori H Osaki
Journal:  Taiwan J Ophthalmol       Date:  2022-02-14

5.  Triamcinolone acetonide injection in the treatment of upper eyelid retraction in Graves' ophthalmopathy evaluated by 3.0 Tesla magnetic resonance imaging.

Authors:  Miao Duan; Dong-Dong Xu; Hai-Long Zhou; Hong-Ying Fang; Wei Meng; Yi-Ning Wang; Zheng-Yu Jin; Yu Chen; Zhu-Hua Zhang
Journal:  Indian J Ophthalmol       Date:  2022-05       Impact factor: 2.969

6.  Alteration of Connective Tissue Growth Factor (CTGF) Expression in Orbital Fibroblasts from Patients with Graves' Ophthalmopathy.

Authors:  Chieh-Chih Tsai; Shi-Bei Wu; Pei-Chen Chang; Yau-Huei Wei
Journal:  PLoS One       Date:  2015-11-24       Impact factor: 3.240

7.  Efficacy of Subantimicrobial Dose Doxycycline for Moderate-to-Severe and Active Graves' Orbitopathy.

Authors:  Miaoli Lin; Yuxiang Mao; Siming Ai; Guangming Liu; Jian Zhang; Jianhua Yan; Huasheng Yang; Aimin Li; Yusha Zou; Dan Liang
Journal:  Int J Endocrinol       Date:  2015-06-29       Impact factor: 3.257

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.